A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model

A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model

The blockade of programmed cell death-1 (PD1) and its ligand PDL1 has been proven to be a successful immunotherapy against several cancers. Similar to cancer, PD1 contributes to the establishment of several chronic infectious diseases, including malaria. While monoclonal antibodies (mAbs) targeting...

Full description

Bibliographic Details
Main Authors: Timothy W. Phares, Vinayaka Kotraiah, Deshapriya S. Karunarathne, Jing Huang, Cecille D. Browne, Peter Buontempo, Marc Mansour, Amy R. Noe, Michelle N. Wykes, James Pannucci, Moriya Tsuji, Gabriel M. Gutierrez
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Immunology
Subjects:
T-cell
vaccine
malaria
peptide
therapeutic
programmed cell death-1
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01377/full

Similar Items

Similar Items